Market Insights - Industry Research Report

Canine Arthritis Market

Canine Arthritis Treatment Market By Treatment (NSAIDs, Opioids, Stem Cell Therapy, Allogeneic Stem Cells, Autologous Stem Cells), Route of Administration (Oral Canine Arthritis Treatment, Injectable Canine Arthritis Treatment), Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies, Drug Stores, e-Commerce) and Region- Global Industry Analysis, 2024 To 2032

Canine Arthritis Treatment Market Size and Trends

The global canine arthritis treatment market was valued at US$ 2.42 billion in 2023. The demand for canine arthritis treatment medications is expected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching a market valuation of US$ 3.73 billion by 2032.

The global canine arthritis treatment market is experiencing significant growth, driven by rising pet ownership and increasing awareness of pet health. Canine arthritis, a common condition in aging dogs, affects joints and mobility, leading to pain and reduced quality of life. Owners are becoming more proactive in seeking treatments, including pharmaceuticals, dietary supplements, and physical therapies, to improve their pets’ well-being.

Pharmaceutical treatments, particularly non-steroidal anti-inflammatory drugs (NSAIDs), dominate the market due to their efficacy in managing pain and inflammation. However, there is a growing demand for alternative and complementary therapies, such as nutraceuticals, which include glucosamine and chondroitin supplements. These options are preferred by pet owners looking for natural, less invasive treatments.

Technological advancements are also shaping the market. Innovations in veterinary medicine, such as regenerative therapies (stem cell therapy and platelet-rich plasma), are gaining traction for their potential to repair and regenerate damaged tissues. Additionally, the development of new drug formulations and delivery methods, such as long-acting injections and transdermal patches, offer more convenient and effective treatment options.

The market is highly competitive, with key players focusing on expanding their product portfolios and geographic reach. Increased investment in research and development, along with strategic collaborations and partnerships, are expected to drive further growth in the canine arthritis treatment market in the coming years.

Competitive Landscape

Major companies and manufacturers in the canine arthritis treatment market, including Boehringer Ingelheim International GmbH, DAIICHI SANKYO COMPANY, LIMITED, Thorne, NUTRI-VET, American Regent, Inc., and DSM, are heavily investing in research and development to innovate new medications, supplements, and therapeutic approaches. These companies are also expanding their distribution networks and forming partnerships with veterinary clinics, pet retailers, and online platforms to enhance the market reach and accessibility of their products to pet owners.

Category-wise Insights

Pet Owners are Increasingly Preferring NSAIDs for Canine Arthritis Treatments

The NSAIDs category is projected to hold the largest share of the canine arthritis treatment market in 2024, accounting for 72% of the global market. The demand for NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) has skyrocketed in recent decades due to their high effectiveness in relieving pain and inflammation associated with canine arthritis. Veterinary professionals frequently prescribe NSAIDs due to their proven effectiveness and safety profile in managing arthritis symptoms in dogs, making them the most sought-after treatment option for pet owners.

Attributes

  • Drug Class: NSAIDs
  • Market Share: 72.00%
Veterinary Professionals are Prescribing Oral Treatments for Canine Arthritis

The market is also segmented by route of administration into oral and injectable treatments, with the oral segment dominating at 70% market share in 2024. Both pet owners and veterinary professionals are increasingly choosing oral treatments for their convenience in administration. Oral treatments offer easy integration into a dog’s daily routine and provide flexibility in dosing and administration schedules. This minimizes the risk of complications associated with injectable therapies, such as injection site reactions.

Attributes

  • Route of Administration: Oral
  • Market Share: 70.00%

Recent Developments

TVM’s DogStem Therapy (January 2023): TVM introduced DogStem, Europe’s first licensed stem cell therapy for canine osteoarthritis. Clinical trials have shown its efficacy in improving gait and orthopedic examination results. Pet owners reported enhanced mobility and quality of life for their dogs, with effects lasting up to eighteen months.

Elanco’s Galliprant Launch (May 2019): Elanco launched Galliprant, a new treatment for canine osteoarthritis pain, in the UK. Galliprant targets the EP4 receptor, reducing pain and inflammation without affecting gastrointestinal and kidney functions. It offers a promising solution for managing osteoarthritis discomfort in dogs.

Rejuvenate Bio’s Gene Therapy Partnership (February 2024): Rejuvenate Bio partnered with a leading animal health company to develop and commercialize groundbreaking gene therapy for canine osteoarthritis. This therapy aims to address the condition’s widespread prevalence and severe consequences, potentially revolutionizing dog health.

Key Companies in the Market

  1. Boehringer Ingelheim International GmbH
  2. DAIICHI SANKYO COMPANY, LIMITED
  3. Thorne
  4. NUTRI-VET
  5. American Regent, Inc.
  6. DSM
  7. Zoetis
  8. National Hog Farmer
  9. Novasep
  10. Bayer AG
  11. Matsun Nutrition

Canine arthritis treatment Market by Segmentation

By Treatment:

  1. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  2. Opioids
  3. Stem Cell Therapy
    • Allogeneic Stem Cells
    • Autologous Stem Cells

By Route of Administration:

  1. Oral Canine Arthritis Treatment
  2. Injectable Canine Arthritis Treatment

By Distribution Channel:

  1. Veterinary Hospitals & Clinics
  2. Retail Pharmacies
  3. Drug Stores
  4. e-Commerce

By Region:

  1. North America
  2. Latin America
  3. Asia Pacific
  4. Middle East and Africa (MEA)
  5. Europe

Frequently Asked Questions

The global canine arthritis treatment market is expected to be worth US$ 2.54 billion by 2024.
The market for canine arthritis treatments is projected to reach US$ 3.73 billion by 2032.
The canine arthritis treatment market is growing at a CAGR of 4.90% from 2024 to 2032.
Key companies in the market include Boehringer Ingelheim International GmbH, DAIICHI SANKYO COMPANY, LIMITED, Thorne, NUTRI-VET, American Regent, Inc., DSM, and others.
The global valuation for the canine arthritis treatment market in 2023 was US$ 2.42 billion.

Share

Get in Touch with Us

Artificial Intelligence Market

Artificial Intelligence Market Size, Share, Growth & Trends Analysis Report By Solution, By Technology (Deep Learning, Machine Learning, NLP, Machine Vision, Generative AI), By Function, By End-use, By Region, And Segment Forecasts, 2025 – 2033

Read More »
Building Materials Market

Building Materials Market Size, Share, Growth & Trends Analysis Report By Type (Aggregates, Bricks, Cement, Others), By Application (Residential, Commercial, Industrial), By Region, And Segment Forecasts, 2025 To 2033

Read More »